Diagnostic and Therapeutic Advances in Hepatology
Version of Record online: 30 NOV 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 54, Issue 6, pages 2254–2258, December 2011
How to Cite
Maddur, H. and Kwo, P. Y. (2011), Boceprevir. Hepatology, 54: 2254–2258. doi: 10.1002/hep.24773
Potential conflict of interest: Paul Kwo has received consulting fees from Abbott, Anadys, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Johnson and Johnson, Merck, Novartis, and Vertex. He has also received fees for non–continuing medical education/continuing education services directly from Bristol-Myers Squibb, Gilead, Merck, Roche, and Vertex and contract research funding from Abbott, Anadys, Bayer, Bristol-Myers Squibb, Conatus, GlaxoSmithKline, Gilead, Merck, Novartis, Roche, and Vertex.
- Issue online: 30 NOV 2011
- Version of Record online: 30 NOV 2011
- Accepted manuscript online: 16 NOV 2011 09:46AM EST
- Manuscript Accepted: 25 OCT 2011
- Manuscript Received: 24 OCT 2011
Additional Supporting Information may be found in the online version of this article.
|HEP_24773_sm_SuppFig1.rtf||1293K||Supporting Figure 1. SVR by IL28B polymorphism from the SPRINT-2 trial.|
|HEP_24773_sm_SuppTable1.rtf||23K||Supporting Table 1. Drugs Contraindicated With Boceprevir Therapy|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.